טוען...
P12 A PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC REOLYSIN(®) IN PATIENTS WITH BRAIN TUMOURS
INTRODUCTION: Oncolytic viruses preferentially replicate in, and kill cancerous cells. REOLYSIN(®) is a proprietary isolate of reovirus type 3 Dearing. In two trials using intralesional administration in gliomas and recurrent brain tumours, REOLYSIN(®) has been well tolerated, with early signs of ef...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4200888/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou249.11 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|